Last reviewed · How we verify
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Coly-Mycin M | COLISTIMETHATE SODIUM | Ph Health | Polymyxin-class Antibacterial | 1970-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Ph Health · 1 drug in Pseudomonas Respiratory Tract Infection in Cystic Fibrosis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Pseudomonas Respiratory Tract Infection in Cystic Fibrosis:
- Pseudomonas Respiratory Tract Infection in Cystic Fibrosis treatment updates — RSS
- Pseudomonas Respiratory Tract Infection in Cystic Fibrosis treatment updates — Atom
- Pseudomonas Respiratory Tract Infection in Cystic Fibrosis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Pseudomonas Respiratory Tract Infection in Cystic Fibrosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pseudomonas-respiratory-tract-infection-in-cystic-fibrosis. Accessed 2026-06-10.
Related
- Pseudomonas Respiratory Tract Infection in Cystic Fibrosis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing